Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2605541 vs Insulin Glargine in Type 1 Diabetes (IMAGINE 3)
NCT01454284Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2012
- Primary completion
- Feb 2014
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of insulin peglispro in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Hemoglobin A1c at 52 weeks. Started Jan 2012; status: completed.
02
Drugs
insulin peglispro
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01454284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01454284.